Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_99505f5f312672820e9f78c254c00a4d |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375 |
filingDate |
2016-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2019-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fdd424b2ae7539cc91b17a0e273c2f68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0f2d202f05a4d98cddf81ba5bfe8aa5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0eda62e9818dbb2eadd59c9310ab321d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae47d5b117e1c400af7cb113bc3e0bbe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_059715e2cba95fead110bc268d90ff05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f93d0fd9a4b842040fd3de359463d878 |
publicationDate |
2019-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-10322133-B2 |
titleOfInvention |
Synthetic lethal drug combination for treating renal cell carcinoma |
abstract |
The present invention pertains to a novel treatment of renal cell carcinoma and other a solid tumors which harbor a VHL inactivation, based on the combination of a first agent inhibiting a protein kinase CK2 (CK2) and a second agent inhibiting an Ataxia Telangiectasia Mutated (ATM) kinase. |
priorityDate |
2015-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |